(HSD11B2). Women frequently complain of acne, hirsutism, and oligomenorrhea [3]. The 23 differential diagnosis in these situations is PCOS, especially with mild or subclinical 24 hypercortisolism. Clinical clues that are helpful to the diagnosis of ACC are the concomitant 25 existence of a Cushingoid phenotype with signs of marked androgen excess, with cancer-1 related symptoms (anorexia, cachexia, mass effect). With rapidly growing tumors, cancer-2 related features dominate the clinical presentation. ACC can also cause deep venous 3 thrombosis or pulmonary embolism due to either cortisol excess or malignancy [3] . Moreover, 4 the presence of cortisol excess may consistently increase the toxicity of chemotherapy since it 5 is associated with immune depression that may favor infections particularly in the 6 neutropenia phase. Cortisol excess should be excluded in all patients with suspected ACC, 7 even if they do not present with typical Cushing features [7] . 8
A detailed hormonal work-up (Table 1) should be performed preoperatively in all patients 9 with suspected ACC for the following reasons: 10 i)
Demonstration of steroid excess establishes the adrenocortical origin of the 11 tumor, while other differential diagnoses are being ruled out (i.e. lymphoma, 12 sarcoma); 13
ii)
The steroid profile may be helpful to evaluate the malignant potential (i.e. 14 estradiol excess in males, high concentration of dehydroepiandrosterone 15 sulphate -DHEAS-or steroid precursors); 16
iii)
Presence of autonomous cortisol secretion in a patient with ACC indicates a risk 17 of post-operative adrenal insufficiency, which can be potentially life-18 threatening; 19 iv) Demonstration of steroid excess at baseline establishes tumor markers that can 20 be useful to detect persistence or recurrence of disease postoperatively [3, 8] . 21 A standard 1 mg overnight dexamethasone test (1-mg DST) is recommended to exclude 22 autonomous cortisol secretion in accordance with low or suppress levels of ACTH, 23 similar with adrenal incidentaloma [7] This test has higher sensitivity (95% at a cortisol 24 threshold of 1.8 μg/dL), compared with 24-h urinary-free cortisol (UFC) which is not helpful 25 in cases of mild hypercortisolism [10] . If cortisol levels following the 1-mg DST are not 1 suppressed despite lack of overt Cushing syndrome, the condition of autonomous cortisol 2 secretion may be present. The recent guidelines of the European Society of Endocrinology and 3 the European Network for the Study of Adrenal Tumors (ENSAT) promoted this definition to 4 the classic "subclinical Cushing's syndrome" [7] . Autonomous cortisol secretion is certain for a 5 cortisol levels above 5 μg/dL after 1-mg DST, while values between 1.8 μg/dL and 5 μg/dL 6 require additional investigation to confirm the diagnosis [7] . Recognizing asymptomatic 7 cortisol excess preoperatively identifies the patients who benefit from glucocorticoid 8 replacement in anesthesia induction and after adrenalectomy and during follow-up [11] . 9
Aldosterone-producing ACC is rare and is generally associated with severe hypertension and 10 marked hypokalemia [12] . Screening by measuring plasma aldosterone and plasma renin 11 activity (PRA) (or direct renin concentration) is recommended in all hypertensive and/or 12 hypokalemic patients with adrenal masses [13] . In some cases, pseudo-aldosteronism is 13 present, due to increased production of deoxycorticosterone. Pure estrogen excess is rare and 14 may cause gynecomastia, loss of libido and testicular atrophy in men, while in women 15 menstrual irregularities [8] . Hypersecretion of sexual steroids is frequently associated to 16 cortisol excess in ACC patients. Baseline 17-OH progesterone levels are frequently increased, 17 as well as androstenedione and DHEAS, which leads to increased plasma testosterone in 18 females with signs of androgen excess (hirsutism, acne, alopecia) [3] . Measurement of 19 steroid precursors in blood or urine may be exploited for diagnostic purposes. However, the 20 value of increased DHEAS levels to predict malignancy of an adrenal mass is rather low [14] . 21
More recently, it was demonstrated that serum steroid paneling by LC-MS/MS is a useful tool 22 to discriminate ACC from other adrenal tumor lesions. In this study, both the number of 23 steroids secreted in high amounts and the marked elevation of several steroid intermediates 24 without biological activity was characteristic of ACC and useful for the differential diagnosis.
7
The cortisol precursor 11-deoxycortisol was found the most discriminating between ACC and 1 non-ACC adrenal lesions [15] . 2 Assessment of plasma or urine fractionated metanephrines is recommend in patients with 3 suspected ACC to exclude a pheochromocytoma, and avoid misdiagnosis and unexpected 4 intraoperative complications [3, 7, 16] . Pertinently, the radiological imaging of 5 pheochromocytoma may appear as a large, heterogeneous and hypervascularized mass 6 mimicking ACC and rarely pheocromocytoma may present with hypercortisolism, being 7 due to ectopic ACTH production [17] . 8
Finally, the hormonal assessment is fundamental because treatment should be directed 9 toward both cancer and hormones, and the therapeutic approach varies according to the stage 10 at diagnosis and clinical conditions of patients. However, it is important to recognize non-11 specific symptoms due to the mass effect, including abdominal discomfort (nausea, 12 vomiting, abdominal fullness) and back pain, while classical malignancy-associated 13 symptoms such as weight loss, night sweats, fatigue or fever are less frequently 14 observed [8] . 15 [3, 4, 6]. Currently, the ENSAT staging system is the most frequently used and allows a 9 adrenalectomy (OA) is recommended; on the contrary, a localized ACC (I-II stage) can be 1 removed by laparoscopic adrenalectomy (LA) or by OA [6], although the use of laparoscopic 2 approach in this setting is still debated. Literature is indeed discordant: Huynh and colleagues 3
All patients with suspected or proven ACC should be discussed in a multidisciplinary
[24] showed that use of LA may decrease survival in patients with stage II ACC, while most 4 of the other studies failed to demonstrated significant different outcomes between LA and 5 OA [25] [26] [27] [28] . In these studies, the recurrence rate was 54%, 50%, 53%, and 49%, 6 respectively, after LA compared to 61%, 64%, 65%, and 64%, respectively, after OA. 7
However, a study raised concern about the most frequent occurrence of peritoneal is associated with a significant benefit in terms of RFS regardless of the hormone secretory 18 status [35] . Advantage in OS was less evident but this may be explained by the fact that 19 mitotane was introduced as treatment of ACC recurrence in most patients. Despite its 20 retrospective nature, this study remains the most informative piece of evidence on the topic 21 and represents a reference for decision making in ACC patients. Strengths of the study are the 22 inclusion of contemporary groups of matched patients, who were allocated to treatment or 23 follow-up based on the treatment policy the center.
Conversely, in many studies patients with unfavorable characteristics were more likely 1 selected for adjuvant mitotane, thus introducing a bias. An example of this may be found in a 2 recent study reporting a multicenter, retrospective analysis on 207 ACC patients, showing 3 that adjuvant mitotane was associated with decreased RFS. However, 42% of the patients 4 treated with mitotane had stage IV ACC and, indeed, chemotherapy was frequently associated 5 to mitotane therapy [36] . A retrospective study from the University of Michigan confirmed the 6 finding that adjuvant mitotane treatment is associated with a significantly improved RFS 7
although it failed to prolong significantly OS [37] . The lack of effect on OS may be explained 8 with the short follow-up (25.6 months). 9
Despite controversy on this issue, there is general agreement on the adjuvant use of mitotane 10 following surgical removal of ACC in high-risk patients. The condition of high risk of 11 recurrence has been defined as stage III, or Ki-67 >10%, or Rx-R1 resection by a panel of 12 international experts [38] . For low risk patients, who are characterized by stage I or II, R0 13 resection and Ki-67 ≤10%, adjuvant mitotane therapy is not mandatory. An international, 14 multicentric, prospective, randomized trial (ADIUVO trial) is currently enrolling low-risk ACC 15 patients, who are randomized to mitotane or observation, in order to definitely establish the 16 effectiveness of adjuvant mitotane in this set of patients. 17
It is common practice in expert centers to monitor regularly blood mitotane concentrations 18 during treatment and to target levels of 14-20 mg/L [39] . A retrospective analysis 19 demonstrated that blood mitotane concentrations ≥14 mg/L were associated with a 20 prolonged RFS in patients treated with adjuvant mitotane following macroscopically radical 21 surgery [40] . Thus, maintenance of target mitotane concentration may represent a predictor 22 of response to adjuvant treatment. 23
There is no consensus on how to start treatment: the ESMO guidelines [38] recommend that 24 mitotane therapy should be administered following a high-dose regimen with the aim of reaching a daily dose of 6 g/daily rather soon and then adjust the dose according to 1 tolerability and mitotane levels. In our personal practice, we start treatment at lower doses 2 (Table 2) because they are better tolerated and less patients have to discontinue treatment 3 [29] . Adjuvant mitotane treatment is started as soon as possible and usually no longer 4 than 12 weeks following surgery, even if there are no data showing what is the best 5 timing. Duration of adjuvant mitotane therapy has not been definitively established, but it is 6 reasonable to continue therapy for at least 2 years, because this is the period when most of 7 ACC recurrences are detected. In our practice, we have currently extended treatment till to 3 8 to 5 years, if tolerated. 9
The most common unwanted effects are gastrointestinal manifestations that appear early in 10 the course of treatment, independently on mitotane levels [41] . Diarrhea and nausea are 11 particularly frequent and can be managed with temporary dose reduction and supportive 12 therapy. Elevated g-glutamyl-transferase levels are also frequently observed but are not 13 actually troublesome unless values are exceedingly elevated. Clinically significant liver 14 toxicity is characterized by a marked increase in transaminases and bilirubin, but is 15 infrequently observed in the absence of predisposing conditions [39] . Central neurologic 16 toxicity (cerebellar symptoms, disturbed cognitive performance) is more closely associated 17 with elevated mitotane concentrations (20 mg/L) but subtler symptoms, such as memory 18 impairment or attention deficit, may be observed in some patients even at lower drug 19 concentrations [42] . In this context, monitoring of circulating mitotane levels may be useful to 20 tailor individually the therapy and limit side effects thus attaining better compliance to 21 treatment. The implementation of blood mitotane monitoring, through a service provided in 22
Europe by the company distributing Lysodren® (Lysosafe, www.lysodren-europe.com), has 23 rendered the use of this drug more feasible because it is possible to some extent to anticipate 24 and prevent toxicity. In our current practice, measurement of circulating mitotane A general measure to deal with mitotane toxicity is a step down to the previously tolerated 8 dose, or temporary drug withdrawal in the event of severe manifestations ( Table 2) . 9
However, well-informed and motivated patients are able to cope with side effects and 10 maintain compliance to treatment. To accomplish this task, it is important to establish a close 11 patient-physician relationship to induce and maintain adherence to treatment. Patients seek 12 advice frequently, also because their local physicians are unfamiliar with mitotane use and its 13 attendant complications, and it is necessary to give a timely counseling to keep patients on 14
treatment. 15
Mitotane has a wide range of effects on the endocrine system and may potentially cause 16 several endocrine disturbances that should be carefully managed ( Table 3) that are still to be completely elucidated. Mitotane administration is associated with low FT4 25 levels without a compensatory rise in TSH, an effect that becomes apparent early in the 1 course of treatment. This prompts thyroxin replacement, even if the benefit of this measure 2 may be difficult to appreciate [42, 44] . In women, gonadal function is usually preserved and 3 most female patients have regular cycles unless PRL levels are significantly increased [6, 42, 4 44] due to a weak estrogen-like action of mitotane [45] . Conversely, in men mitotane 5 treatment causes sexual dysfunction as a late but common unwanted effect, due to inhibition 6 of testosterone secretion. Sex steroid replacement may become necessary to treat 7 hypogonadism in some patients but may worsen gynecomastia [6, 42, 44] . Mitotane use is 8 associated with increasing levels of LDL and HDL cholesterol, and triglycerides [46]. However, 9
the value of introducing statins remains uncertain although patients may be worried about 10 their lipid levels. The decision to use anti-lipid drugs, which may further complicate 11 supportive therapy and is not exempt from potential toxicity, should be carefully though at 12 considering patient life expectancy. Side effects of mitotane treatment are showed in 13 Table 4 . 14 Another option is adjuvant radiotherapy, that in a retrospective analysis from the United 15
States was reported to decrease of 4.7 times the risk of local failure compared with surgery 16 alone [47] . In a retrospective analysis from the German ACC Registry, radiotherapy in an 17 adjuvant setting resulted in a significant better 5-year RFS, but did not affect OS and disease-18 free survival [48] . However, no difference between surgery plus radiotherapy and surgery 19 alone was found in another retrospective study done in the United States [49] . A review of the 20 literature concluded that adjuvant radiotherapy should be considered in patients with 21 incomplete, or R1 resection, or Rx resection, who are at high risk for local recurrence [50]. A 22 total dose of >40 Gy with single fractions of 1.8 Gy to 2 Gy should be administered. However, 23 prospective investigations are required and no definitive conclusions are available at the 24 moment. 1 on 3982 ACC patients from the National US Cancer Data Base (NCDB), revealing that adjuvant 2 chemotherapy was performed in 10% of cases. However, the study was not able to capture in 3 how many cases cytotoxic agents or mitotane have been used as adjuvant chemotherapy. By 4 comparing these subjects with those treated with surgery only, OS was not different, while no 5 RFS analysis was reported [51] . Anecdotal cases reported a more favorable outcome after an 6 adjuvant etoposide -cisplatin based chemotherapy [52] . A phase II clinical trial reported that 7 the combination of mitotane plus streptozotocin was effective in an adjuvant setting. 8
However, the study design does not allow discriminating the relative merits of the two drugs 9
[53]. 10 11
TREATMENT OF ADVANCED DISEASE 12
About 50% of newly diagnosed ACC patients present with metastatic or unresectable disease 13
[38] and, as previously said, most ACC that underwent initial complete resection are doomed 14 to develop recurrent or metastatic disease [38, 39] . The prognosis of patients with 15 advanced/metastatic ACC is generally poor but it is heterogeneous and long-term survivors 16 have been described [39, 54] . The management of these patients is mainly centered on 17 systemic therapy including mitotane alone or mitotane in combination with chemotherapy. 18
The standard chemotherapy regimen for advanced ACC is EDP (etoposide, doxorubicin and 19 cisplatin) plus mitotane (EDP-M). This scheme was introduced in a multicenter prospective 20 phase II study conducted in Italy [20 55 ]. More recently, its efficacy was compared against the 21 combination of streptozotocyn and mitotane (Sz-M) in a prospective randomized phase III 22 clinical trial conducted worldwide [56] . Three hundred and four patients were prospectively 23 enrolled in about 6 years. Patients with disease progression to the first-line treatment 24 received the alternate regimen. EDP-M was superior to Sz-M both in terms of disease response rate and progression-free survival (PFS). Analysis of OS also favored patients 1 initially randomized to receive EDP-M but due to the attenuating effect of the cross over to 2 EDP-M of patients who progressed to Sz-M, the difference failed to attain statistical 3 significance. In addition to systemic therapy also loco-regional therapies, i.e. surgery [57, 58] , 4 radiofrequency ablation (RFA) [58, 59] , and chemoembolization [60] can be taken into 5 consideration in a selected patient population. Moreover, in patients, who have 6 contraindications to EDP, or poor performance status, either cisplatin or carboplatin 7 administered as single agents could be reasonable options. 8
It is worth of note that there is a small subgroup of patients with advanced/metastatic ACC 9
presenting an oligo-metastatic disease with favorable prognostic factor and/or a relatively 10 long disease-free interval from previous surgery (i.e. 12 months or more). These patients 11 have a relative long survival perspective and may not benefit from an aggressive systemic 12 treatment such as the EDP-M regimen. Therefore, single agent mitotane could be a reasonable 13 option. Mitotane is often associated with loco-regional approaches in the treatment of these 14 patients. Surgery of primary and or metastases can be recommended if a complete resection 15 (R0) is achievable. Surgery of multiple metastases is considered on a case-by-case basis and 16 should be performed mainly in patients with favorable prognostic factors, sustained disease 17 response to systemic therapy, and long-term R0 resection expectations. In patients who are 18 not candidates for surgery, percutaneous image-guided RFA is a locally effective treatment 19 and chemoembolization is another possibility to treat liver metastases. RFA in combination 20 with surgical resection may allow better disease control in the setting of limited disease [58-21 60 ]. Tumor debulking generally offers little benefit, however surgery of primary disease in 22 newly diagnosed patients with oligo-metastatic disease and limited exta-adrenal tumor 23 volume can be performed in case of good response to systemic therapy. It should be noted 24 that the efficacy of local regional therapies in the management of such patients has never been 25 assessed in a randomized prospective clinical trial, so we cannot exclude that the long-term 1 benefit obtained in some cases can be ascribed to a patient selection. In the author opinion, 2 the long-term benefit is due at least in part to the efficacy of systemic therapy; therefore, it is 3 recommended that all local regional approaches should be used in combination with systemic 4 therapy. 5
On the contrary, the majority of metastatic ACC patients have poor prognostic features (i.e. 2 6 or more organ involved). For these patients, chemotherapy with EDP-M regimen represents 7 the treatment of choice. In case of painful metastasis, palliative radiotherapy is an option, 8 especially in bone lesions. Due to the latency of mitotane to attain the therapeutic range, the 9 drug administered alone is not indicated in the management of patients with clinical evidence 10 of fast growing tumors. Metastatic ACC submitted to EDP-M regimen have a survival 11 perspective of 18 months as demonstrated by the results of the FIRM-ACT trial [56]. However, 12 15% of patients are alive after 5 years. In terms of PFS, 50% of patients submitted to EDP-M 13 showed disease progression after 5 months, and 25% of patients were free from progression 14 after 12 months, and 15% after 2 years. In addition, few patients were still alive and free from 15 progression after 5 years [56] . These data show that the efficacy of chemotherapy plus 16 mitotane is overall modest, but a small subset of patients is destined to obtain a long-term 17 disease control. The identification of factors that may predict chemotherapy efficacy is very 18 important to select patients destined to benefit from this aggressive strategy and to address 19 non-responding patients to experimental therapies. In a recently published paper, our group 20 has demonstrated that the expression of topoisomerase II was associated with EDP-M efficacy 21
[61]. These data need confirmation. It should be noted, however, that EDP is usually 22 administered for a maximum of 6-8 cycles while mitotane is usually maintained till 23 progression. It is possible that cytotoxic chemotherapy is useful to attain rapid tumor 24 shrinkage but the long-term efficacy observed in some cases could be attributed to the 25 mitotane maintenance. If this is true, predictive factors of mitotane efficacy are 1 needed. Human cytochrome P450 2B6 (CYP2B6) [62] and CYP2W1 [63] that are involved in 2 mitotane metabolism and may activate mitotane in the adrenocortical tissue, respectively, or 3 ribonucleotide reductase large subunit 1 (RRM1) gene expression [64] are promising 4 predictive factors of mitotane efficacy. The value of these potential predictive factors should 5 be assessed in prospective studies. 6
Finally, regarding second-line therapy, the results of patients with disease progression to 7 platinum-containing regimens plus mitotane were as a whole modest. The association of 8 gemcitabine to metronomic capecitabine showed a limited activity in a prospective 9 multicenter phase II trial conducted in Italy 
ENDOCRINE MANAGEMENT OF CORTISOL SECRETING ACC 1
The morbidity caused by ACC and its prognosis derives not only from the spread of malignant 2 cells into other organs but also from the consequences of hormone excess. Consequently, the 3 goals of treatment in ACC include both control of tumor growth and mitigation of the effects 4 derived from hormone excess in patients with hormone-secreting ACC. As uncontrolled 5 hypercortisolism strongly impacts on quality of life and may cause a precocious death, a rapid 6 control of hormone hypersecretion is mandatory. Mitotane has both anti-secretive and anti-7 proliferative activity; however, the slow onset of mitotane activity is a main limitation for the 8 management of Cushing's syndrome [26] . On a separate note, it is important to offer advice about the potential concerns of 24 becoming pregnant after removal of an ACC. There is limited evidence suggesting that pregnancy may trigger ACC recurrence and that pregnancy in patients with past or 1 current ACC may be associated with worse prognosis [75, 76]. Moreover, pregnancy 2 should be avoided while being exposed to mitotane, due to its potential teratogenic 3 effects. In this context, it is important to recognize that mitotane levels may remain 4 measurable for many months following discontinuation of treatment. undertaken, and treatments should be given in expert centers. In these centers, patients may 18 be offered the chance to participate in clinical trials with experimental drugs due to the 19 limited availability of current therapeutic choices. 20
21

Five-year view: 22
Recent studies [77], [78] provided great advances in the understanding of molecular 23 pathogenesis of ACC and led to the definition of groups characterized by different molecular 24 signature and different prognosis. It is expected that over the next few years the use of these molecular markers will be applicable in clinical practice thus representing the cornerstone for 1 prognostication and stratifying treatment strategy. This will be the first step toward a 2 personalized therapy; as instance, patients in the "good prognosis group" may be potentially 3 spared adjuvant mitotane treatment while patients in the "poor prognosis group" may be 4 treated more intensively. As to adjuvant mitotane treatment, the conclusion of the ongoing 5 ADIUVO and ADIUVO-2 study, which is about to be launched, will provide important data for 6 defining the value of adjuvant mitotane in either "low-risk" or "high-risk" patients. Finally, 7 molecular studies will hopefully detect targets that can be druggable, thus paving the way for 8 future targeted therapies with more efficacy and less toxicity compared to the current 9 therapeutic options. This remains the most urgent need in the management of advanced ACC. 10 11
KEY ISSUES 12
• Adrenocortical carcinoma (ACC) is a rare tumor that should be diagnosed and treated 13 promptly due to its very aggressive behavior. 14 • ACC is frequently associated with Cushing's syndrome that may have severe clinical 15 consequences, including a strong impact on quality of life and reduction of life 16 expectancy. 17
• Surgery is the treatment of choice and should be attempted whenever radical resection 18 is feasible. 19
• Despite radical surgery, ACC has a high propensity to recur, particularly when adverse 20 prognostic factors are present. 21
• Mitotane is the only approved drug for ACC and is used either as adjuvant treatment 22 following surgical removal of the tumor or palliative treatment for advanced disease. 23
• Mitotane is a difficult drug to manage and either monitoring of circulating levels or 24 institution of appropriate supportive therapy is a key to limit drug-related toxicity. 
